Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Official Title

An Open-Label Multicentre Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Summary:

The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.

Trial Description

Primary Outcome:

  • Number of Participants with Dose-limiting Toxicities (DLTs)
  • Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Secondary Outcome:
  • Area under the Plasma Concentration-time Curve from Time 0 Through the Last Measurable Point (AUC0-t) of H3B-6527
  • Maximum Observed Plasma Concentration (Cmax) of H3B-6527
  • Time of Maximum Observed Plasma Concentration (tmax) of H3B-6527
  • Objective Response Rate (ORR)
  • Duration of Response (DOR)
  • Progression-free Survival (PFS)
  • Overall Survival (OS)
  • Time to Response

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society